Bruce Psaty and the risks of calcium channel blockers

Quality and Safety in Health Care

Volumn 11, Issue 3, 2002, Pages 294-296

  Deyo, R A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; PHYSICIAN; RISK FACTOR; SHORT SURVEY;

EID: 0036753348     PISSN: 09638172     EISSN: None     Source Type: Journal    
DOI: 10.1136/qhc.11.3.294     Document Type: Short Survey

References (17)

1. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
2. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.
3. Deyo RA, Psaty BM, Simon G, et al. The messenger under attack: Intimidation of researchers by special-interest groups. N Engl J Med 1997;336:1176-80.
4. Stryer DB, Lurie P, Bero LA. Dear Doctor ⋯ regarding calcium channel blockers. JAMA 1996;275:517.
5. Horton R. Bayer accused of disinformation. Lancet 1995;346:891-2.
6. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study MIDAS. A randomized controlled trial. JAMA 1996;276:785-91.
7. Pahor M, Psaty BM, Alderman MH, et al. Health outcames associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomized controlled trials. Lancet 2000;356:1949-54.
8. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: Results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists Collaboration. Lancet 2000;356:1955-64.
9. Pahor M, Psaty BM, Alderman MH, et al. Blood-pressure-lowering treatment (letter). Lancet 2001;358:152-3.
10. Furberg CD, Psaty BM, Pahor M, et al. Clinical implications of recent findings from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) and other studies of hypertension. Ann Intern Med 2001;135:1074-8.
11. Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs: An up-to-date perspective on the proposed hazards. Arch Intern Med 2001;161:1145-58.
12. Anon. Trend of the month: Global pharmaceutical sales up 11%. Drug Benefit Trends 2001;13:8.
13. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001;285:2719-28.
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renopratective effect of angiotensin-receptar antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
15. Joint National Committee on Prevention Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
16. Maclure M, Dormuth C, Naumann T, et al. Influences of educational interventions and adverse news about calcium-channel blockers on first line prescribing of antihypertensive drugs to elderly people in British Columbia. Lancet 1998;352:943-8.
17. Stelfox HT, Chua G, O'Rourke K, et al. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338:101-6.